Live
- They always want me to win, and now I feel lucky to have been offered a story like ‘Zebra’: Satyadev Kancharana
- ‘Democracy first, humanity first’: PM Modi in Guyana's parliament on two countries' similarities
- PKL Season 11: Telugu Titans register third straight win to top standings
- Is Pollution Contributing to Your COPD?
- NASA Unveils Underwater Robots for Exploring Jupiter's Moons
- Additional Central forces arrive in violence-hit Manipur
- AR Rahman and Saira Banu’s Divorce: Legal Insights into Common Issues in Bollywood Marriages
- 82.7 pc work completed in HPCL Rajasthan Refinery area: official
- Curfew relaxation extended in 5 Manipur districts on Friday
- Tab scam prompts Bengal govt to adopt caution over fund disbursement
Granules generic pain reliever gets FDA nod
Granules India Ltd on Thursday announced that the US Food and Drug Administration approved its Abbreviated New Drug Application (ANDA) for Acetaminophen 650 mg Tablets, Extended Release, a generic version of Tylenol 650mg tablets, Extended Release
Hyderabad: Granules India Ltd on Thursday announced that the US Food and Drug Administration approved its Abbreviated New Drug Application (ANDA) for Acetaminophen 650 mg Tablets, Extended Release, a generic version of Tylenol 650mg tablets, Extended Release.
Acetaminophen 650 mg extended release tablets are used primarily for temporary pain management including arthritis relief, said the city-based drug maker.
"The addition of Acetaminophen 650mg, extended release tablets to our OTC ( Over the Counter) portfolio leverages several components of our value proposition," Krishna Prasad Chigurupati, CMD of Granules India said.
Granules India is the only supplier that is equipped with backward integration up to the Active Pharmaceutical Ingredient of this product, he added.
"With a capacity of over 24,000 tonnes per annum Acetaminophen API and finished dosage capacity of more than 18 billion units/year, we are confident that we will ensure supply security to our customers which will support us to capture our target market share," Chigurupati said.
